At a moment when medication therapy for sickle cell disease (SCD) leaves too many behind and widespread access to curative gene therapies still lies in the distant future, automated red blood cell exchange is experiencing renewed interest. To improve patients’ lives, a broad commitment is needed to expand access to transfusion therapies.
Each year, about 13.9 million units of red cells or whole blood are transfused in the U.S. Blood transfusions come with some risks, particularly the danger that the recipient will contract a life threatening illness from contaminated blood. In an effort to make the process of blood transfusions safer and to improve outcomes, a biotechnology […]
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.